UBS’s Lifecore Biomedical LFCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$4K Buy
+300
New +$3.75K ﹤0.01% 9620
2014
Q2
Sell
-100
Closed -$1K 10636
2014
Q1
$1K Sell
100
-1,200
-92% -$13.2K ﹤0.01% 10216
2013
Q4
$16K Buy
1,300
+800
+160% +$9.55K ﹤0.01% 8422
2013
Q3
$6K Hold
500
﹤0.01% 9262
2013
Q2
$7K Buy
+500
New +$6.91K ﹤0.01% 8983

Other funds holding LFCR

UBS's LFCR Position: Q3 2014 in Review

UBS reduced its Lifecore Biomedical (LFCR) stake by 7.7% in Q3 2014, selling an estimated $15.2K and leaving 14,620 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #5303.

UBS first reported a position in LFCR in Q2 2013 and has held it in 6 quarters since. The position peaked at $198K in Q2 2014. 107 funds tracked by Wall St. Rank hold LFCR as of Q3 2014.

  • UBS held 14,620 shares of Lifecore Biomedical worth $179K as of Q3 2014.
  • UBS sold 1,216 Lifecore Biomedical shares in Q3 2014, an estimated $15.2K.
  • Lifecore Biomedical made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5303 holding.
  • UBS first reported a position in Lifecore Biomedical in Q2 2013 and has held it in 6 quarters since.
  • UBS's Lifecore Biomedical position peaked at $198K in Q2 2014.
  • 107 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.